louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03739164: Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)
Official title: Complete Robotic Tampa Associating Microwave Liver Ablation With Portal Vein Ligation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Liver Cancer
Liver Tumor
Hepatocellular Carcinoma
Hilar Cholangiocarcinoma
Lead sponsor: Florida Hospital Tampa Bay Division
Sponsor class: OTHER
First posted: 2018-11-13
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults between the ages of 18 and 80 with indication for hepatectomy of \>70% liver volume

Brief summary: This is a study following the outcomes and survival of patients undergoing the TAMLAPS hepatectomy at Florida Hospital Tampa by Dr. Iswanto Sucandy


Eligibility criteria: Inclusion Criteria

* Patients scheduled to undergo the TAMLAPS procedure by Dr. Iswanto Sucandy.

Exclusion Criteria:

* Subjects with history of noncompliance.
* Subjects with physical health, substance abuse, or mental health problems that will limit the subject's ability to meet study requirements

Primary outcomes:
measure: Growth of the Future Liver remnant
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tampa
country: United States
facility: Florida Hospital Tampa
state: Florida
Study officials:
References:
Clinical trial NCT02029664: Gait Control of Stroke Patients Using Visual Feedback
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stroke
Lead sponsor: National Rehabilitation Center, Seoul, Korea
Sponsor class: OTHER_GOV
First posted: 2014-01-08
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine the possibility of gait pattern change via visual feedback among patients with stroke. Also, the optimal visual feedback would be chosen from this study.


Eligibility criteria: Inclusion Criteria:

* Hemiplegic stroke patients \>= 18 years old
* Functional Ambulation Category \>=3
* Cognitively intact enough to follow the study protocol
* Adults without any gait problem

Exclusion Criteria:

* Quadriplegic stroke patients
* Orthopedic problems to affect gait
* Underlying other neurological or psychological disorders
* Spasticity or contracture which impede the gait.
* Uncontrolled medical problems
* Pregnant.

Primary outcomes:
measure: Step length symmetry
timeFrame: Participants will be followed for the duration of treadmill gait, an expected average of 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: National Rehabilitation Center
Study officials:
affiliation: National Rehabilitation Center
name: Joon-Ho Shin, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01470664: FST-100 in the Treatment of Acute Adenoviral Conjunctivitis
Official title: A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Adenoviral Conjunctivitis
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2011-11-11
Enrollment: 176
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute adenoviral conjunctivitis.


Eligibility criteria: Inclusion Criteria:

* Have a clinical diagnosis of suspected acute adenoviral conjunctivitis in at least one eye.

Exclusion Criteria:

* Have a known sensitivity to any of the components of FST-100 or FST-100 vehicle.

Primary outcomes:
measure: Adenoviral eradication and clinical resolution of the infection
timeFrame: 6-7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Andover
country: United States
facility: Ora, Inc.
state: Massachusetts
city: Noida
country: India
facility: Ora, Inc.
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05171764: Dual Energy Cardiac CT Data Collection and Evaluation
Official title: Feasibility and Data Collection of Dual Energy Cardiac CT on a Wide Coverage System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Diseases
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
Collaborators: name: University Hospital, Zürich
First posted: 2021-12-29
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects will be enrolled that will be undergoing a routine cardiac CT imaging scan. Subjects will be representative of the general population expected to undergo cardiac CT imaging as standard of care clinical practice.

Brief summary: This study is intended to collect clinical feasibility data using this prototype research mode for the purposes of understanding potential clinical impact, potential limitations and strengths, and to further develop the technique through development of image reconstruction and processing approaches or identification of other areas of development required.

Detailed description: Up to 38 subjects may be enrolled to achieve the target number of 30 evaluable subjects. Withdrawn or discontinued subjects who are enrolled and received the investigational scan, may be replaced. Subject participation will be deemed complete once the diagnostic and investigational scans are completed. A subject is considered evaluable when images and raw data from the diagnostic single energy cardiac CT scan and raw data from the investigational dual energy cardiac CT scan have been collected successfully and demonstrate a diagnostic interpretation.

Eligibility criteria: Inclusion Criteria:

1. Patients \> 50 years old undergoing routine cardiac CT imaging exam;
2. Patients that within last 12 months did not undergo medical procedures involving ionizing radiation;
3. Signed informed consent.

Exclusion Criteria:

1. Contradictions to contrast;
2. Contraindications for beta blocker;
3. BMI \>30;
4. High heart rate ≥75 BPM;
5. Atrial Fibrillation;
6. Arrythmia or irregular heartbeats;
7. Pregnant women;
8. Patients lacking capacity in providing informed consent
9. Patients who did participate in prior research studies with ionizing radiation in the last 12 months.

Primary outcomes:
measure: Collect Data
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Evaluation- Likert Scale
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: Zürich University Hospital
Study officials:
affiliation: GE Healthcare
name: Melissa Challman
role: STUDY_DIRECTOR
References:
Clinical trial NCT04105764: Deep NMB in Ambulatory Gynecological Laparoscopy
Official title: Deep Neuromuscular Blockade to Improve Postoperative Quality of Recovery in Ambulatory Gynaecologic Laparoscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Muscle Relaxation
Lead sponsor: Ain Shams University
Sponsor class: OTHER
Collaborators: name: Elite medical center
First posted: 2019-09-26
Enrollment: 80
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Gynecological laparoscopic surgery is commonly performed as an ambulatory basis for the aim of rapid discharge, reduce hospital stay with reduced costs and to improve postoperative QOR \[1,2\]. However, the creation of pneumoperitoneum during laparoscopy may cause postoperative pain and other physiological changes \[3\], which could influence the postoperative QOR negatively \[4\]. Poor postoperative QOR leads to prolonged hospital stay \[5\].

Detailed description: Deep NMB is known to improve surgical conditions and pneumoperitoneium related complications in laparoscopic surgery \[6,7,8,9\]. However, it is unknown whether deep NMB improves postoperative QOR in ambulatory gynecological laparoscopy.

Therefore, we designed a double blind randomised trial to compare the effects of deep and moderate NMB on postoperative QOR in ambulatory gynecological laparoscopic surgery. We hypothesized that deep NMB improves postoperative QOR, compared to moderate NMB. The primary outcome was postoperative QOR in POD1. The secondary outcome was quality of surgical conditions, pain scores, time to meet PACU and hospital discharge, and opioid consumption

Eligibility criteria: Inclusion Criteria:

* ASA I and II

Exclusion Criteria:

* Neuromuscular disorders

Primary outcomes:
measure: Quality of recovery
timeFrame: 24 hours postoperative
Secondary outcomes:
measure: Postoperative pain
timeFrame: During the length of hospital stay post surgery (on average 24 hours)
Other outcomes:
Locations:
city: Kuwait
country: Kuwait
facility: Elite Medical Center
Study officials:
References:
Clinical trial NCT00456664: CMV Disease and IRIS in HIV-1 Infected Persons
Official title: Molecular Diagnostics for CMV Disease and IRIS in HIV-1 Infected Persons, and the Mechanism Study for CMV Alternative Gene Splicing in Immediate Early Protein
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV Infections
Cytomegalovirus
Keywords: CMV
IRIS
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2007-04-05
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes

Brief summary: Various diagnostic methods are available for CMV infection. But none of them could be a standard and highly valuable. Our first goal is to setup a series of molecular diagnostic tools for HIV-1 infected person. By using these tools, physicians can easily select cases with CMV disease or immune restoration inflammatory syndrome (IRIS) to enroll this study. Furthermore, we will seek for a predict marker for CMV reactivation, CMV disease and IRIS. Finally, our research will focus on the mechanism of the IE gene alternative splicing between lytic and latent stage.

Detailed description: At present, human cytomegalovirus (HCMV) remains a major health threat in immune compromised patients. Especially HCMV will cause blind and death in HIV-1 infected person. Currently, few antiviral drugs can be chosen for treatment of HCMV infection. Besides, more and more drug resistant virus strains were reported and led failure in antiviral therapy.

Various diagnostic methods are available for CMV infection. Such as shell vial assay, CMV antigen test, pp65 antigen assay and polymerase chain reaction. But none of them could be a standard and highly valuable. Although CMV-PCR is very sensitive, it can't distinguish between active disease and asymptomatic infection or latency, can't predict symptomatic disease nor can't monitor the successful antiviral therapy.

Our first goal is to setup a series of molecular diagnostic tools for HIV-1 infected person. By using these tools, physicians can easily select cases with CMV disease or immune restoration inflammatory syndrome (IRIS) to enroll this study. Furthermore, we will seek for a predict marker for CMV reactivation, CMV disease and IRIS. Finally, our research will focus on the mechanism of the IE gene alternative splicing between lytic and latent stage. We may find out new therapeutic concept and prevent virus reactivation from latency.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of HIV-1 Disease
* Clinical diagnosis of CMV disease or immune restoration inflammatory syndrome (IRIS)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kaoshiung
country: Taiwan
facility: Kaoshing Medical University Chung-Ho Memorial Hospital
Study officials:
affiliation: Chung-Ho Memorial Hospital,Kaohsiung Medical University
name: Jih-Jin Tsai, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04689464: COVID 19 and Psychological Health: a Cross Sectional Study to Evaluate Anxiety and Depression in Covid-19 Patients
Official title: COVID19 and Psychological Health: a Cross Sectional Evaluation of the Risks of Anxiety and Depression Among Patients Diagnosed With Covid 19
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Anxiety
Depression
Keywords: COVID19
Anxiety
Depression
Lead sponsor: AlFayhaa General Hospital
Sponsor class: OTHER
Collaborators: name: University of Basrah
name: Ministry of Health, Iraq
First posted: 2020-12-30
Enrollment: 450
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with covid19 diagnosed by their healthcare providers

Brief summary: The covid-19 pandemic started to spread worldwide since December 2019. It promoted to an exaggerated psychological stress and anxiety in humans due to the intolerable symptoms higher than usual death of many infected patients. This study examines the corona related anxiety and if there is need for drug intervention to treat this anxiety.

To answer these questions, a survey made to the hospitalized patients including sex, age, educational level, Marital state, and a standardized questionnaires (GAD-7 and PHQ-9) which has been validated and shown to possess good psychometric qualities in studies of participants from multiple populations.


Eligibility criteria: Inclusion Criteria:

- patients with COVID19 willing to participate in the study

Exclusion Criteria:

* unwilling unable to read or interact with standardized questionnaire unconscious

Primary outcomes:
measure: depression
timeFrame: at the time of acute infection, average of 1 month
measure: anxiety
timeFrame: at the time of acute infection, average of 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Basra
country: Iraq
facility: AlFayhaa Teaching hospital
Study officials:
affiliation: University of Basrah
name: Zainab N Abdul-nabi, M.Sc.
role: STUDY_DIRECTOR
affiliation: University of Basrah
name: Hiba Dawood, M.Sc.
role: STUDY_DIRECTOR
affiliation: AlFayhaa teaching hospital
name: Qussay N Almaliki, Ph.D.
role: STUDY_DIRECTOR
affiliation: University of Basrah
name: Nadheera F Neamah
role: STUDY_DIRECTOR
affiliation: Al-Sader teaching hospital
name: Dania Zydoon
role: PRINCIPAL_INVESTIGATOR
affiliation: Al-Mawani general hospital
name: Zainab Mahdi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01499264: Efficacy of MySkin Patch for the Healing of Burn Wounds: a Randomised Controlled Trial
Official title: Efficacy of MySkin Patch for the Healing of Burn Wounds: a Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Burns
Burn Injury
Hydrogel Bandage
Occlusive Dressings
Keywords: MySkin patch
Lead sponsor: Associazione Infermieristica per lo studio delle Lesioni Cutanee
Sponsor class: OTHER
Collaborators: name: Artsana S.p.a.
First posted: 2011-12-26
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of clinical efficacy of my skin (hydrogel and polyurethane film) plus best practice clinical care in subjects with burn injuries with particular regard to: 1) Wound healing (complete reepithelialization), 2) the patient's pain. In the context of the study will be collected secondary outcomes related to type of lesion and its clinical evolution through the analysis of the items in the scale of the PSST.


Eligibility criteria: Inclusion Criteria:

* Presence of at least one injury burn covered by a dressing of 10x8 cm (80 cm2)
* Injury treated with medication in use at the center
* Patients assisted at the emergency care, or at the outpatient
* Extension of the lesion less than 80 cm2 (including dressings in cm10x8cm)
* Patient age greater than or equal to 18 years
* Patients who have given consent to enrollment in the trial and the processing of personal data
* Patient / lesion that has already been recruited in the study or who have previously passed a period of 10 days (washout) of "no treatment" according to the research protocol

Exclusion Criteria:

* A end-stage of disease
* Suspected or known allergic diathesis to the product of medication
* Subjects that do not give consent to data processing
* Dry lesion with necrosis or eschar
* Presence of both local and systemic infection or inflammation
* Injuries that to the decision of the provider of care, needs a targeted local treatment other than as provided for in the Protocol
* Patient / lesion that has already been previously recruited into the study, before a period of 10 days (washout) of suspension from the same research protocol
* Patients who use alternative medicine treatments such as aloe

Primary outcomes:
measure: Wound healing and Significant reduction in pain
timeFrame: 1 month
Secondary outcomes:
measure: Clinical evaluation of the lesion scores for each visit, the presence / absence of infection for each visit
timeFrame: 1 month
Other outcomes:
Locations:
city: Rozzano
country: Italy
facility: Istituto Clinico Humanitas - IRCCS
state: Milano
city: Busto Arsizio
country: Italy
facility: Ospedale di Circolo di Busto Arsizio
state: Varese
Study officials:
affiliation: Associazione Infermieristica per lo studio delle Lesioni Cutanee
name: Patrizia Tomasin
role: STUDY_DIRECTOR
References:
Clinical trial NCT00435864: Natural Killer Index From Hematopoietic Stem Cell Graft
Official title: Pilot, Multicenter and Prospective Study of the Natural Killer Index From Hematopoietic Stem Cell Graft at a Genotypic, Phenotypic and Functional Level
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Lymphoblastic Leukemia
Acute Myeloblastic Leukemia
Chronic Myeloid Leukemia
Keywords: recipient of a HSC graft in Acute Myeloblastic Leukemia therapy
recipient of a HSC graft in others pathologies treated in hematology of Nantes university hospital or Angers university hospital
donors are healthy subjects
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2007-02-16
Enrollment: 92
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Numerous studies about the potential role of NK alloreactive during a n hematopoietic stem cells graft are based on genotypical analyses of the KIR receptors and on genotypic incompatibilities between KIR and HLA for couple donor/recipient. There is still a lot of issues non resolved: Are KIR really expressed and how occur their expression during time when hematopoietic reconstitution? Is it depending on HLA of the recipient?If KIR are expressed, what are the mechanisms of alloreactivity of NK cells? Are NK able to lyse tumoral cells? Could alloreactive NK cells constitute a therapeutic tool able to induce tolerance and elimination of leukemia during hematopoietic stem cells grafts?


Eligibility criteria: Inclusion Criteria:

* Age superior to 1 year
* Patient that will be treated by an HSC graft
* Initial pathology of recipient: acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic myeloid leukemia

Exclusion Criteria:

* Patient already included in a study with an exclusion period
* HIV + or HCV + serology during pre-graft analysis
* Patient already treated by an allograft of HSC

Primary outcomes:
measure: Estimate in the pilot study the percentage of different NK cell populations during hematopoietic reconstitution after HSCT with regard to the KIR and HLA genotypes of donor / recipient
timeFrame: J60 post-HSCT
Secondary outcomes:
measure: Genetic analysis of KIR and HLA incompatibility of donor and recipient - Rate of in vitro amplification of NK cells from the donor - Assess the percentage of NK cells from the donor
timeFrame: J60 post-HSCT
Other outcomes:
Locations:
city: Nantes
country: France
facility: CHU de Nantes
Study officials:
affiliation: Nantes University Hospital
name: Françoise Mechinaud, md
role: PRINCIPAL_INVESTIGATOR
affiliation: Nantes University Hospital
name: Patrice Chevallier, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Nantes University Hospital
name: Nadège Corradini, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital, Angers
name: Norbert Ifrah, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05531864: Ultrasound-guided Continuous Low Serratus Anterior Plane Block in Hepatocellular Carcinoma Surgery
Official title: The Role of Continuous Low Serratus Anterior Plane Block in Hepatocellular Carcinoma Surgery: a Randomised Clinical Trial.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Liver Neoplasms
Postoperative Analgesia
Serratus Anterior Plane Block
Keywords: serratus anterior plane block
Postoperative analgesia
liver cancer
Lead sponsor: The First People's Hospital of Neijiang
Sponsor class: OTHER
First posted: 2022-09-08
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To investigate the clinical application of ultrasound-guided continuous low serratus anterior plane block in open surgery for hepatocellular carcinoma.

Detailed description: METHODS: Patients with hepatocellular carcinoma who attended our hospital from January 2021 to April 2023 were divided into CS group and N group according to the random number table method; CS group underwent ultrasound-guided continuous low anterior serratus plane block and N group underwent ultrasound-guided single anterior serratus plane block combined with rectus abdominis sheath block; the operation time, anesthesia time, incision length, sensory block time and sensory block maintenance time were counted and recorded. Pain score (NRS) was used to detect analgesia; alanine aminotransferase (ALT), liver function aspartate aminotransferase (AST), and prothrombin time (The time of thrombin, NRS) were measured by fluorescent quantitative PCR. （The time of thrombin (APTT), total bilirubin (TBIL) levels and adverse reactions.

Eligibility criteria: Inclusion Criteria:

1. Age 18-60 years;
2. ASAI-II;
3. BMI: 18-29 kg/m2

Exclusion Criteria:

1. Combined cardiac, cerebral, hepatic, and renal failure;
2. Comorbid psychiatric and neuromuscular disorders;
3. A history of allergy to anesthetic drugs;
4. Participation in other recent clinical or drug trials.

Primary outcomes:
measure: Block plane
timeFrame: 30 minute after the surgery begins
measure: visual analogue scale
timeFrame: 24 hours after surgery
measure: visual analogue scale
timeFrame: 48 hours after surgery.
measure: visual analogue scale
timeFrame: 36 hours after surgery.
Secondary outcomes:
measure: Patient satisfaction
timeFrame: 48 hours after surgery.
measure: Remedial analgesic drug
timeFrame: 24 hours after surgery.
measure: Intraoperative blood pressure changes
timeFrame: 2 hours after the beginning of surgery.
measure: Intraoperative heart rate changes
timeFrame: 2 hours after the beginning of surgery.
Other outcomes:
Locations:
city: Neijiang
country: China
facility: The First People's Hospital of Neijiang
state: Sichuan
Study officials:
affiliation: First People's Hospital of Neijiang.
name: ailing wu, Doctor
role: STUDY_DIRECTOR
References: